Biopharma Disruption: 2026 Tech Opportunities for Founders
Biopharma is changing fast. See 5 key tech opportunities for founders in 2026, from AI drug discovery to blockchain supply chains.
Biopharma is changing fast. See 5 key tech opportunities for founders in 2026, from AI drug discovery to blockchain supply chains.
Can new robotaxi startups survive by 2026? Learn about the $500M funding hurdle, regulations, and public trust challenges they face.
Agrobio biotech startups face new compliance risks in 2026. Learn why early FDA/EPA engagement and a strong QMS are critical for success.
IMF revises 2026 global growth to 2.8%. Understand why this matters for founders, with insights on interest rates, supply chains, and emerging markets.
AgriGen faces a patent crisis for its gene-edited soybean. Learn why defining genetic modifications is key for biotech IP and future food security.
70% of CRISPR ag-tech patents are corporate. Startups: learn how to secure early patents, differentiate claims, and attract investors.
High interest rates mean startups must prioritize profit over growth for funding in 2026. Learn how VC focus shifts to unit economics and self-sufficiency.
Founders face 2026 hurdles in humanoid robotics. Learn capital needs (>$50M), ethical issues, and team structures for success.
Founders, understand 2026 PCAOB scrutiny. Learn to build audit regulator relationships, ensure compliance, and protect investor trust.
How TerraHarvest CEO Aisha Rahman plans to manage 2026 geopolitical risks. Learn 5 key strategies for supply chains, cybersecurity, and scenario planning.